APA

Layton A. M., Schaller M., Homey B., Hofmann M. A., Bewley A. P., Lehmann P., Nohlgård C., Sarwer D. B., Kerrouche N. & Ma Y. M. (20161014). Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. : Journal of the European Academy of Dermatology and Venereology : JEADV.

Chicago

Layton A M, Schaller M, Homey B, Hofmann M A, Bewley A P, Lehmann P, Nohlgård C, Sarwer D B, Kerrouche N and Ma Y M. 20161014. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. : Journal of the European Academy of Dermatology and Venereology : JEADV.

Harvard

Layton A. M., Schaller M., Homey B., Hofmann M. A., Bewley A. P., Lehmann P., Nohlgård C., Sarwer D. B., Kerrouche N. and Ma Y. M. (20161014). Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. : Journal of the European Academy of Dermatology and Venereology : JEADV.

MLA

Layton A M, Schaller M, Homey B, Hofmann M A, Bewley A P, Lehmann P, Nohlgård C, Sarwer D B, Kerrouche N and Ma Y M. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. : Journal of the European Academy of Dermatology and Venereology : JEADV. 20161014.